Abstract library

770 results for "NET biomarker diagnosis".
#1694 Plasma Protein Fingerprinting for the Diagnosis of Small Intestinal Neuroendocrine Tumors (siNETs)
Introduction: siNETs are notoriously difficult to diagnose, especially in an early stage.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD PhD Magnus Kjellman
#435 Olfactory Receptor 51E1 is a Novel Potential Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumors (SI-NETs) get late diagnosis. We discovered the olfactory receptor 51E1 (OR51E1) as a potential target to develop as a novel biomarker.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Tao Cui
Authors: Cui T, Ryberg U, Li S C, Cunningham J, ...
#491 International Survey for the Use of Biomarkers and Molecular Imaging in Neuroendocrine Tumors (NET): What we are Using in Daily Practice
Introduction: Several guidelines have given recommendations for optimal use of biomarkers and molecular imaging. However, those guidelines’ implementation may not be always possible due to local policies or lack of access to several diagnostic studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: DR CHRISTOS Toumpanakis
#583 Olfactory Receptor 51E1 is a Potential Novel Tissue Biomarker for the Diagnosis and Prognosis of Small Intestine Neuroendocrine Tumors
Introduction: Small intestine neuroendocrine tumor (SI-NET) patients get late diagnosis. We reported olfactory receptor 51E1 (OR51E1) as a SI-NET-mRNA marker.
Conference:
Category: Basic
Presenting Author: Mr TAO CUI
#899 Evaluation of the Clinical Utility of Plasma Biomarkers in Diagnosis of Neuroendocrine Tumors
Introduction: Neuroendocrine tumors (NETs) are rare cancers that usually develop in the gastroenterohepatic system. Diagnostic workup of these tumors includes measurement of plasma levels of marker peptides. Clinical experience suggests that these markers may be misleading if used before histological or imaging evidence of a NET is available.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: Matthew Lunberg-Adams
Authors: Lunberg-Adams M, James A, Perros P, ...
#1278 Midkine is a New Novel Serum Biomarker in Small Intestinal Neuroendocrine Tumors (SI-NETs).
Introduction: SI-NETs are often diagnosed late, which limits curative treatment options.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Kosmas Daskalakis
Keywords: Biomarker, SI-NET
#2220 Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors
Introduction: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Professor Mark Kidd
#2083 Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study
Introduction: Predicting treatment response at an early stage in the treatment algorithm for NET is highly desirable.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: Associate prof, Magnus Kjellman
#2173 Decreased Serum Amyloid A1 as Potential Diagnostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Introduction: Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with an increased incidence reported in recent years. Researchers have shown that tumor cells produce and secrete more exosomes compared with normal cells. Serum amyloid A1 (SAA1) is elevated in patients with liver cancer, lung cancer, breast cancer, prostate cancer and endometrial cancer. However, the relation between SAA1 and GEP-NENs remains unclear.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: He Na
Authors: Na H, Qiyun T, ...
#413 Expression of UCH-L1 in PETs and its Implications
Introduction: There is a lack of reliable biomarkers to distinguish benign from malignancy in pancreatic endocrine tumors (PETs) and to predict prognosis. Our previous study on insulinoma found the expression of UCH-L1 in these tumors. The diagnostic or prognostic value of this protein has not been well demonstrated in PETs.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr Yuan-Jia Chen
Authors: Chen Y J, Qiao X W, Tang L, Wan Y H, ...